OBJECTIVES: We set out to examine the prevalence and persistence of mutations conferring high-level nonnucleoside reverse transcriptase (NNRTI)-resistance in a cohort of HIV-infected children who had failed prophylaxis to prevent mother-to-child-transmission (PMTCT). DESIGN: A prospective observational cohort study at the Pediatric HIV Clinic at Kalafong Provincial Tertiary Hospital in Pretoria, South Africa. METHODS: Children referred for initiation of antiretroviral therapy (ART) were enrolled from July 2010 through February 2013. HIV drug resistance testing was performed using the oligonucleotide ligation assay (OLA) on dried blood spots (DBS) collected at enrolment and monthly follow-up visits for 2 years. RESULTS: South African children who failed HIV-prophylaxis had a high prevalence of NNRTI-resistant HIV (46/88; 52%). Among children with NNRTI-resistance, the frequency of the predominant resistant variant in each child's HIV-quasispecies was high (median 96%) at study entry (median age 7.5 months), and in 26 out of 27 followed a median of 13 months persisted at a high frequency (median 89%). CONCLUSION: Our finding that infants who fail HIV-prophylaxis frequently have long-lived NNRTI-resistant HIV suggests that resistance will likely persist through 36 months of age, when children qualify for NNRTI-based ART. These children may benefit from HIV drug resistance testing to guide selection of their treatment.
OBJECTIVES: We set out to examine the prevalence and persistence of mutations conferring high-level nonnucleoside reverse transcriptase (NNRTI)-resistance in a cohort of HIV-infectedchildren who had failed prophylaxis to prevent mother-to-child-transmission (PMTCT). DESIGN: A prospective observational cohort study at the Pediatric HIV Clinic at Kalafong Provincial Tertiary Hospital in Pretoria, South Africa. METHODS:Children referred for initiation of antiretroviral therapy (ART) were enrolled from July 2010 through February 2013. HIV drug resistance testing was performed using the oligonucleotide ligation assay (OLA) on dried blood spots (DBS) collected at enrolment and monthly follow-up visits for 2 years. RESULTS: South African children who failed HIV-prophylaxis had a high prevalence of NNRTI-resistant HIV (46/88; 52%). Among children with NNRTI-resistance, the frequency of the predominant resistant variant in each child's HIV-quasispecies was high (median 96%) at study entry (median age 7.5 months), and in 26 out of 27 followed a median of 13 months persisted at a high frequency (median 89%). CONCLUSION: Our finding that infants who fail HIV-prophylaxis frequently have long-lived NNRTI-resistant HIV suggests that resistance will likely persist through 36 months of age, when children qualify for NNRTI-based ART. These children may benefit from HIV drug resistance testing to guide selection of their treatment.
Authors: Ingrid A Beck; Wenjie Deng; Rachel Payant; Robert Hall; Roger E Bumgarner; James I Mullins; Lisa M Frenkel Journal: J Clin Microbiol Date: 2014-04-16 Impact factor: 5.948
Authors: Shahin Lockman; Roger L Shapiro; Laura M Smeaton; Carolyn Wester; Ibou Thior; Lisa Stevens; Fatima Chand; Joseph Makhema; Claire Moffat; Aida Asmelash; Patrick Ndase; Peter Arimi; Erik van Widenfelt; Loeto Mazhani; Vladimir Novitsky; Stephen Lagakos; Max Essex Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Mark A Micek; Ana Judith Blanco; Ingrid A Beck; Sandra Dross; Laurinda Matunha; Pablo Montoya; Kristy Seidel; Soren Gantt; Eduardo Matediane; Lilia Jamisse; Stephen Gloyd; Lisa M Frenkel Journal: Clin Infect Dis Date: 2010-05-15 Impact factor: 9.079
Authors: Deborah Persaud; Paul Palumbo; Carrie Ziemniak; Jie Chen; Stuart C Ray; Michael Hughes; Peter Havens; Murli Purswani; Aditya H Gaur; Ellen Gould Chadwick Journal: J Infect Dis Date: 2007-04-05 Impact factor: 5.226
Authors: Julie A E Nelson; Ali Fokar; Michael G Hudgens; Kara J Compliment; Justin Tyler Hawkins; Gerald Tegha; Deborah D Kamwendo; Dumbani Kayira; Innocent A Mofolo; Athena P Kourtis; Denise J Jamieson; Charles M Van Der Horst; Susan A Fiscus Journal: AIDS Date: 2015-10-23 Impact factor: 4.177
Authors: S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson Journal: AIDS Date: 2001-10-19 Impact factor: 4.177
Authors: Jessica D Church; Saad B Omer; Laura A Guay; Wei Huang; Jessica Lidstrom; Philippa Musoke; Francis Mmiro; J Brooks Jackson; Susan H Eshleman Journal: J Infect Dis Date: 2008-10-01 Impact factor: 5.226
Authors: Mark A Micek; Sandra Dross; Ana Judith Blanco; Ingrid A Beck; Laurinda Matunha; Kristy Seidel; Pablo Montoya; Eduardo Matediana; Soren Gantt; Stephen Gloyd; Lisa Frenkel Journal: J Infect Dis Date: 2014-03-04 Impact factor: 5.226
Authors: Nava Yeganeh; Tara Kerin; Bonnie Ank; D Heather Watts; Margaret Camarca; Esau C Joao; Jose Henrique Pilotto; Valdilea G Veloso; Yvonne Bryson; Glenda Gray; Gerhard Theron; Ruth Dickover; Mariza G Morgado; Breno Santos; Regis Kreitchmann; Lynne Mofenson; Karin Nielsen-Saines Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Nikki Higa; Amy Pelz; Donald Birch; Ingrid A Beck; Tatiana Sils; Pearl Samson; Mutsawashe Bwakura-Dangarembizi; Carolyn Bolton-Moore; Edmund Capparelli; Ellen Chadwick; Lisa M Frenkel Journal: J Pediatric Infect Dis Soc Date: 2020-04-30 Impact factor: 3.164
Authors: Ceejay L Boyce; Tatiana Sils; Daisy Ko; Annie Wong-On-Wing; Ingrid A Beck; Sheila M Styrchak; Patricia DeMarrais; Camlin Tierney; Lynda Stranix-Chibanda; Patricia M Flynn; Taha E Taha; Maxensia Owor; Mary Glenn Fowler; Lisa M Frenkel Journal: Clin Infect Dis Date: 2022-06-10 Impact factor: 20.999
Authors: Sydney J Bennett; Catherine Chunda-Liyoka; Lisa K Poppe; Katie Meinders; Chisanga Chileshe; John T West; Charles Wood Journal: AIDS Date: 2020-10-01 Impact factor: 4.632